Promising combo for brain metastases hits early snag: trial ends after just one patient
NCT ID NCT05553522
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial aimed to see if combining three drugs (tucatinib, trastuzumab, and capecitabine) with precise radiation (SRS) is safe for people with HER2-positive breast cancer that has spread to the brain. Only one person enrolled before the study was terminated, so we have very little information. The main goal was to find the safest dose and watch for side effects like low blood counts or radiation-related issues.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tucatinib, trastuzumab, capecitabine, and stereotactic radiosurgery
- What this could lead to
- If it works, this could point toward a treatment that controls brain metastases from HER2-positive breast cancer using a combination of targeted drugs and precise radiation.
- What could go wrong
- This was a very early Phase 1 trial with only 1 participant and was terminated, so we have almost no data on safety or effectiveness. The combination may cause serious side effects like low blood counts or lung inflammation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Miami Cancer Institute at Baptist Health, Inc.
Miami, Florida, 33176, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?